JPH10194986A - 移植肝機能改善・再生促進剤 - Google Patents
移植肝機能改善・再生促進剤Info
- Publication number
- JPH10194986A JPH10194986A JP9168177A JP16817797A JPH10194986A JP H10194986 A JPH10194986 A JP H10194986A JP 9168177 A JP9168177 A JP 9168177A JP 16817797 A JP16817797 A JP 16817797A JP H10194986 A JPH10194986 A JP H10194986A
- Authority
- JP
- Japan
- Prior art keywords
- tcf
- liver
- immunosuppressant
- proliferation factor
- hepatocyte proliferation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003908 liver function Effects 0.000 title claims abstract description 18
- 230000008929 regeneration Effects 0.000 title abstract description 10
- 238000011069 regeneration method Methods 0.000 title abstract description 10
- 229960003444 immunosuppressant agent Drugs 0.000 claims abstract description 15
- 230000001861 immunosuppressant effect Effects 0.000 claims abstract description 15
- 239000003018 immunosuppressive agent Substances 0.000 claims abstract description 15
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 20
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 230000001172 regenerating effect Effects 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 abstract description 57
- 238000002054 transplantation Methods 0.000 abstract description 28
- 108090000623 proteins and genes Proteins 0.000 abstract description 12
- 102000004169 proteins and genes Human genes 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract description 7
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 7
- 239000000243 solution Substances 0.000 abstract description 7
- 210000002950 fibroblast Anatomy 0.000 abstract description 6
- 229960001967 tacrolimus Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 102100031702 Endoplasmic reticulum membrane sensor NFE2L1 Human genes 0.000 abstract 6
- 101000588298 Homo sapiens Endoplasmic reticulum membrane sensor NFE2L1 Proteins 0.000 abstract 6
- 210000003494 hepatocyte Anatomy 0.000 abstract 5
- 230000035755 proliferation Effects 0.000 abstract 5
- 239000001963 growth medium Substances 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 238000011694 lewis rat Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 208000007204 Brain death Diseases 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940072288 prograf Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9168177A JPH10194986A (ja) | 1996-06-10 | 1997-06-10 | 移植肝機能改善・再生促進剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17055596 | 1996-06-10 | ||
| JP31553296 | 1996-11-12 | ||
| JP8-315532 | 1996-11-12 | ||
| JP8-170555 | 1996-11-12 | ||
| JP9168177A JPH10194986A (ja) | 1996-06-10 | 1997-06-10 | 移植肝機能改善・再生促進剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10194986A true JPH10194986A (ja) | 1998-07-28 |
| JPH10194986A5 JPH10194986A5 (enExample) | 2005-03-03 |
Family
ID=27322970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9168177A Pending JPH10194986A (ja) | 1996-06-10 | 1997-06-10 | 移植肝機能改善・再生促進剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH10194986A (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005298392A (ja) * | 2004-04-09 | 2005-10-27 | Kissei Pharmaceut Co Ltd | 肝移植後の拒絶反応の予防または治療用医薬組成物 |
| WO2006077675A1 (ja) * | 2005-01-24 | 2006-07-27 | Kringle Pharma Inc. | 移植臓器の線維化抑制剤 |
| US7115568B2 (en) | 1997-03-14 | 2006-10-03 | Daiichi Pharmaceutical Co., Ltd. | Methods using TCF II |
| US7306791B2 (en) | 1997-03-11 | 2007-12-11 | Daiichi Sankyo Co., Ltd. | Agent for preventing and/or treating multiple organ failure |
-
1997
- 1997-06-10 JP JP9168177A patent/JPH10194986A/ja active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7306791B2 (en) | 1997-03-11 | 2007-12-11 | Daiichi Sankyo Co., Ltd. | Agent for preventing and/or treating multiple organ failure |
| US7115568B2 (en) | 1997-03-14 | 2006-10-03 | Daiichi Pharmaceutical Co., Ltd. | Methods using TCF II |
| US7138372B2 (en) | 1997-03-14 | 2006-11-21 | Daiichi Pharmaceutical Co., Ltd. | Agent for preventing and/or treating cachexia |
| JP2005298392A (ja) * | 2004-04-09 | 2005-10-27 | Kissei Pharmaceut Co Ltd | 肝移植後の拒絶反応の予防または治療用医薬組成物 |
| WO2006077675A1 (ja) * | 2005-01-24 | 2006-07-27 | Kringle Pharma Inc. | 移植臓器の線維化抑制剤 |
| US7696170B2 (en) | 2005-01-24 | 2010-04-13 | Kringle Pharma Inc. | Fibrosis inhibitor for implanted organ |
| US8076289B2 (en) | 2005-01-24 | 2011-12-13 | Kringle Pharma Inc. | Fibrosis inhibitor for implanted organ |
| US8383588B2 (en) | 2005-01-24 | 2013-02-26 | Kringle Pharma Inc. | Fibrosis inhibitor for implanted organ |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4463885B2 (ja) | 劇症肝炎疾患治療剤 | |
| EP0588477B1 (en) | Medicinal composition comprising TCF-II | |
| AU734766B2 (en) | Agent for preventing and/or treating cachexia | |
| JP3030386B2 (ja) | 抗ガン剤 | |
| JPH10194986A (ja) | 移植肝機能改善・再生促進剤 | |
| JPH0640938A (ja) | Ｈｇｆ含有製剤 | |
| US5776464A (en) | Agent for relieving side effects caused by immunosuppressants | |
| JP4006058B2 (ja) | 多臓器不全予防及び／又は治療剤 | |
| JP3619526B2 (ja) | Ｔｃｆ−ｉｉを有効成分とする肝臓疾患治療剤 | |
| JPH1129493A (ja) | 放射線障害予防及び／又は治療剤 | |
| KR100572044B1 (ko) | 패혈증 예방 및/또는 치료제 | |
| JP4006057B2 (ja) | 悪液質予防及び／又は治療剤 | |
| JP3904268B2 (ja) | Ｈｇｆ医薬製剤 | |
| KR100568664B1 (ko) | 악액질 예방 및/또는 치료제 | |
| AU2004200074C1 (en) | Agent for relieving side effects caused by immunosuppressants | |
| KR20000010642A (ko) | 다장기부전 예방 및/또는 치료제 | |
| JP2006089505A (ja) | 虚血性疾患治療剤 | |
| JP2007277268A (ja) | 劇症肝炎疾患治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040326 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040326 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070823 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071211 |